CareLit · DOI-Nachweis · Pneumologie
Pooled analysis of mortality data from the TOMORROW and INPULSIS™ trials of nintedanib in idiopathic pulmonary fibrosis (IPF)
DOI 10.1055/s-0035-1544831
Bibliografische Angaben
Nachweis in CareLit
Autor:innenAM Kirsten, L Richeldi, J Roman, F Le Maulf, C Hallmann, S Stowasser, JA Lasky
ZeitschriftPneumologie
Ausgabe02/2015
Jahrgang / SeitenNicht angegeben
Kernaussage aus der Literatur
Abstract-Vorschau
Background: Nintedanib has been investigated as a treatment for IPF in three randomized, placebo-controlled, 52-week trials: the Phase 2 TOMORROW trial and the two replicate Phase 3 INPULSIS™ trials. Compared with placebo, nintedanib 150 mg twice daily reduced the decline in forced vital capacity (FVC), consistent with a slowing of disease progression. Mortality was a secondary endpoint in all three trials; however,…
Zitieren
Zitierempfehlung
AM Kirsten, L Richeldi, J Roman, F Le Maulf, C Hallmann, S Stowasser, JA Lasky (2015) Pooled analysis of mortality data from the TOMORROW and INPULSIS™ trials of nintedanib in idiopathic pulmonary fibrosis (IPF). Pneumologie (02). https://doi.org/10.1055/s-0035-1544831
Mit CareLit weiterarbeiten